About City of Hope
City of Hope's mission is to deliver the cures of tomorrow to the people who need them today. Founded in 1913, City of Hope has grown into one of the largest cancer research and treatment organizations in the U.S. and one of the leading research centers for diabetes and other life-threatening illnesses. City of Hope research has been the basis for numerous breakthrough cancer medicines , as well as human synthetic insulin and monoclonal antibodies. With an independent, National Cancer Institute-designated comprehensive cancer center at its core, City of Hope brings a uniquely integrated model to patients spanning cancer care, research and development, academics and training, and innovation initiatives. City of Hope's growing national system includes its Los Angeles campus, a network of clinical care locations across Southern California, a new cancer center in Orange County, California, andtreatment facilities in Atlanta, Chicago and Phoenix. City of Hope's affiliated group of organizations includes Translational Genomics Research Institute and AccessHope TM . For more information about City of Hope, follow us on Facebook , Twitter , YouTube , Instagram and LinkedIn .
City of Hope's commitment to Diversity, Equity and Inclusion
We believe diversity, equity and inclusion is key in serving our mission to provide compassionate patient care, drive innovative discovery, and advance vital education focused on eliminating cancer and diabetes in all of our communities. Our commitment to Diversity, Equity and Inclusion ensures we bring the full range of skills, perspectives, cultural backgrounds and experiences to our work -- and that our teams align with the people we serve in order to build trust and understanding. We are dedicated to fostering a community that embraces diversity - in ideas, backgrounds and perspectives; this is reflected in our work and represented in our people.
Dr. David Chen's research group at the Beckman Research Institute of City of Hope is seeking a highly skilled and motivated Postdoctoral Fellow to join their dynamic team. Dr. Chen is a distinguished leader serving as the Director of the Division of Epigenetics and Transcriptional Engineering at City of Hope Cancer Center. The primary focus of his lab revolves around investigating epigenetic mechanisms, drug resistance, and identifying therapeutic targets in various cancers through cutting-edge techniques such as high throughput genetic screens. The lab is proficient in high-throughput CRISPR genetic screens for identifying novel therapeutic targets for cancer treatment. They also leverage next-generation sequencing (NGS) methods like ChIP-seq, ATAC-seq, and RNA-seq for comprehensive epigenomic and transcriptomic analyses and utilize patient-derived xenograft (PDX) models to evaluate the efficacy of potential therapies in vivo. In addition, Dr. Chen's laboratory is involved in cutting-edge technology development including high-density CRISPR tiling scan, precision epigenome editing, and single-cell CRISPR/RNA-seq. Recent publications from the Chen lab include Yang et al. 2021 Nature Communications (PMID: 34210975), Liu et al. 2022 Leukemia (PMID: 34373586), Xu et al. 2022, Science Advances (PMID: 36563143), Li et al. 2023, Advanced Science (PMID: 37075745). Dr. Chen's research group is well-funded, backed by prestigious grants from the National Institutes of Health (NIH), including R37 MERIT, R01s, U54 awards and other foundation (ASH, LLS, ALSF, COSF, SU2C-CRUK) awards. This is an exceptional opportunity for a talented Postdoctoral Fellow to work alongside Dr. David Chen and his accomplished team at City of Hope's Beckman Research Institute. The successful candidate will have the chance to make significant contributions to the field of cancer research while gaining valuable experience in state-of-the-art methodologies and technologies.
Key Responsibilities include:
· We are looking for highly motivated individuals with the ability to work in a team environment. Genuine enthusiasm for science, willingness to think beyond established concepts and to try and learn new experimental and analysis tools.
· Excellent technical skills: able to perform hands-on lab benchwork and/or computational experiments proficiently and independently.
· Generate, interpret, and evaluate data, communicate results in an organized manner.
· Accurate record keeping.
Basic education, experience and skills required for consideration:
· A Ph.D. degree in life or biomedical sciences, or a related discipline (cancer biology, structural biology, computational biology, bioinformatics) is required.
· Good oral and written communication skills in English (required).
· Experience in cell biology, molecular cloning, or animal model studies (highly preferred).
· Experience in CRISPR technology (highly preferred).
· Experience in computational biology, machine learning, R, Python, Perl, UNIX/LINUX, etc. (highly preferred).
· Experience in bioinformatics, transcriptomic, proteomic, epigenetic, molecular dynamic, or protein structural data analysis (highly preferred).
· Experience in protein purification, compound screen, protein/protein or protein/compound interaction (highly preferred).
· Publications from Dr. David Chen lab.
· For more information about Dr. David Chen's lab, please visit here .
· The estimated pay scale represents the typical [salary/hourly] range City of Hope reasonably expects to pay for this position, with offers determined based on several factors which may include, but not be limited to, the candidate's experience, expertise, skills, education, job scope, training, internal equity, geography/market, etc. This pay scale is subject to change from time to time.
· As a condition of employment, City of Hope requires staff to comply with all state and federal vaccination mandates.
City of Hope is committed to creating a diverse environment and is proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, religion, color, national origin, sex, sexual orientation, gender identity, age, status as a protected veteran, or status as a qualified individual with disability.